$VMD

Viemed Healthcare (NASDAQ:VMD) President Michael Moore Sells 31,570 Shares

Viemed Healthcare (NASDAQ:VMD) President Michael Moore sold 31,570 shares of the company's stock on March 18th for approximately $297,389.40, reducing his ownership by 1.83%. This sale is part of a larger pattern of insider selling totaling 136,802 shares between March 18-20. The company's stock fell 5.5% to $8.71 on heavy volume, following recent mixed quarterly results and a "Hold" consensus rating from analysts, despite a "Strong-Buy" upgrade from one firm.

Original reporting
MarketBeat · MarketBeat
Published Mar 21, 2026, 12:16 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 21, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Viemed Healthcare (NASDAQ:VMD) President Michael Moore Sells 31,570 Shares — source image
Decision brief

The 30-second read

$VMDBearishMed
01

Why it matters

The insider sale by the President, combined with a recent stock decline, suggests cautious sentiment among management, potentially reflecting concerns about near-term performance.

02

Market read

The insider activity and stock performance indicate a cautious outlook for VMD in the short term, but fundamental factors should be considered for long-term decisions.

03

What to watch

Recent stock decline could be driven by broader market correction or sector-specific issues unrelated to company fundamentals.

Timing: short-term (next 1-3 weeks)

Background

Viemed Healthcare has experienced mixed quarterly results and recent analyst ratings, with insider selling activity increasing.

Company-level read

Ticker impact

$VMDBearishMedium confidence
Context

Insider selling activity and recent stock performance suggest cautious outlook.

Expected impact

Potential short-term downside of approximately 5-10%, with stabilization possible if fundamentals improve.

Evidence & confidence

Insider sales often signal caution but are not definitive; recent stock decline supports a cautious outlook.

Market effects

Potential negative sentiment affecting healthcare equipment and services sector.

Limited regional impact; company-specific event.

Minimal; company-specific insider activity.

Counterpoint

Insider selling may be part of planned portfolio rebalancing and not indicative of company performance.

Key entities

  • Michael Moore

    President of Viemed Healthcare who sold 31,570 shares.

  • Viemed Healthcare

    Healthcare company specializing in respiratory care equipment.

Related articles

$VMDMedAI 8/10

Viemed Healthcare Q2 Earnings Call Highlights

Viemed Healthcare (NASDAQ:VMD) reported Q2 updates on home respiratory and sleep therapies. Management cited improved ventilator patient growth and said PAP setups rose, with sleep patients up about 5% sequentially and 44% YoY. Equipment sales nearly doubled to $19M. Gross profit was $45M (57.7% margin). Full-year net revenue guidance raised to $314M-$320M and adjusted EBITDA to $64M-$68M.

$VMDHigh

VIEMED HEALTHCARE, INC. (VMD): Results of Operations and Financial Condition

VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease.htm EX-99.1 Document VIEMED HEALTHCARE ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (August 3, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based hea

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).